Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank27
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Latest
-35.95%
↓ 113% vs avg
Percentile
P27
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-16.88%
Historical baseline
PeriodValue
Q3 2025-35.95%
Q2 202528.41%
Q1 2025-19.48%
Q4 2024-36.25%
Q3 2024-9.48%
Q2 20243.32%
Q1 2024-37.95%
Q4 2023-65.94%
Q3 2023-1.14%
Q2 20231.97%
Q1 2023-30.09%
Q4 20220.00%